Nov 2, 2022 8:09 am EDT Ocuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol® and Strategic Partnership with American Society of Ophthalmic Administrators (ASOA)
Oct 24, 2022 8:56 am EDT Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting
Oct 7, 2022 7:00 am EDT Ocuphire Pharma to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference
Oct 6, 2022 9:27 am EDT Ocuphire Pharma Hosting Key Opinion Leader Event on Oral APX3330 for Diabetic Eye Disease
Sep 29, 2022 8:00 am EDT Ocuphire Expands Medical Advisory Board with Seven New KOLs and Strengthens Leadership Team
Sep 27, 2022 7:30 am EDT Opus Genetics Expands Board of Directors with Appointment of Global Ophthalmology Leader Dr. Adrienne Graves
Sep 15, 2022 7:00 am EDT Ocuphire Announces Upcoming Presentations at European Forum 2022, Eyecelerator@AAO 2022 and the American Academy of Ophthalmology 2022 Annual Meeting
Sep 12, 2022 8:34 am EDT Opus Genetics Leadership to Present at 3rd Annual Gene Therapy for Ophthalmic Disorders Conference
Sep 12, 2022 8:00 am EDT Ocuphire Pharma Receives PDFUA Fee Waiver for Nyxol New Drug Application from FDA
Sep 8, 2022 8:00 am EDT Ocuphire Pharma Announces Last Patient Completes Final Visit in ZETA-1 Phase 2b 24-Week Trial of Oral APX3330 in Diabetic Retinopathy